Further re New Drug Application

AstraZeneca PLC 6 December 1999 ASTRAZENECA PHARMACEUTICALS R&D PRESENTATION LIST OF COMPOUNDS AstraZeneca R&D Pipeline: NCEs Cardiovascular Compound Mechanism Indication Phase Estimated Filing MAA NDA ZD4522 Statin Hyperlipidemia III 2Q 2001 2Q 2001 melagatran Thrombin Thrombosis III 2Q 2001 2Q inhibitor (s.c) 2001 H376/95 Thrombin Thrombosis III 2Q 2001 2Q inhibitor (oral) 2001 H376/95 Thrombin Prevention of II 4Q 2003 4Q inhibitor (oral) stroke in AF 2003 AR-C 69931 P2T antagonist TBD II >2002 >2002 (iv) AR-C 126532 P2T antagonist Arterial I 2005 2005 (oral) thrombosis H-327/86 Immunomodulator TBD II >2002 >2002 AR-H039242 PPAR agonist Insulin II 2003 2003 resistance ZD4927 Factor Xa Thrombosis I >2002 >2002 inhibitor H409/22 NPY antagonist TBD II >2002 >2002 H345/52 Class III TBD II >2002 >2002 antiarrhythmic (iv) AR-H 050642 Class III Atrial PC 2005 2005 antiarrhythmic fibrillation (oral) Atacand/HTCZ Angiotensin II Hypertension Filed antagonist/ diuretic ZD0947 K+ channel opener Urinary I >2002 >2002 incontinence Gastrointestinal Esomeprazole Acid pump Acid related GI Filed magnesium inhibitor disease mosapride 5HT modulator Dyspepsia II TBD TBD RAPID Reversible acid Acid related GI I 2004 2004 pump inhibitor disease rofleponide Topical steroid Inflammatory PC 2004 2004 bowel disease Helicobacter Vaccine Helicobacter PC 2007 2007 vaccine eradication Helicobacter Oral treatment Helicobacter PC 2007 2007 project eradication Oncology Faslodex Anti-oestrogen Breast III 3Q 2000 3Q cancer 2000 Iressa Signal Transduction Solid II 4Q 2001 4Q (ZD1839) Inhibitor (Epidermal tumours 2001 Growth Factor receptor tyrosine kinase inhibitor) ZD0473 3rd generation platin Solid II 2Q 2002 2Q (iv) tumours 2002 ZD0473 3rd generation platin Solid PC >2002 >2002 (oral) tumours ZD9331 Thymidilate synthase Solid II 4Q 2001 4Q inhibitor (iv) tumours 2001 ZD9331 Thymidilate synthase Solid II >2002 3Q inhibitor (oral) tumours 2002 ZD6126 Vascular targeting agent Solid PC >2002 >2002 tumours AZD6474 Anti-angiogenic Solid PC >2002 >2002 (Vascular Endothelial tumours cell Growth Factor receptor tyrosine kinase inhibitor) AstraZeneca R&D Pipeline: NCEs Respiratory Compound Mechanism Indicat Phase Estimated Filing ion MMA NDA Symbicort Inhaled steroid/B2 Asthma III 4Q 1999 TBD Turbuhaler agonist Symbicort Inhaled steroid/B2 COPD III 1Q 2001 TBD Turbuhaler agonist ViozanT Dual dopamine/E2 COPD III 3Q 2001 3Q agonist (pMDI) 2001 Viozan Dual dopamine/E2 COPD III 3Q 2001 3Q agonist (TBH) 2003 AR-C 89855 Dual dopamine/E2 COPD PC 2005 2005 agonist RPNS Intranasal steroid Rhinitis II 2004 2004 (rofleponide) seratrodast Thromboxane inhibitor Asthma III TBD TBD ZD8321 Human neutrophil ARDS II TBD TBD elastase inhibitor ZD0892 Human neutrophil COPD I 2004 2004 elastase inhibitor AR-D111421 VIP agonist Asthma II TBD TBD ZD4007 5-lipoxygenase COPD PC 2005 2005 inhibitor NK1/NK2 Dual neurokinase Asthma PC TBD TBD antagonist T3 Dry powder inhaler, Asthma I TBD TBD non-reservoir Pain Control LEF Peripheral II- Acute and II 4Q 2002 4Q agonist chronic pain 2002 LTA Na channel Analgesia II >2002 >2002 blocker ZD6416 EP1 antagonist Chronic pain II >2002 >2002 NO-NSAID Nitric oxide Acute and PC >2002 >2002 NSAID chronic pain derivative Dental Gel Topical Dental III 2Q 2001 2Q anaesthesia anaesthesia 2001 Delta Delta opioid Acute and PC agonist chronic pain Oral glycine NMDA Antagonist Neuropathic pain PC CNS Zendra GABA modulator Stroke III 4Q 2001 1Q 2001 AR-R15896 NMDA Stroke II 3Q 2002 3Q 2002 antagonist NXY-059 Radical Stroke II 3Q 2002 3Q 2002 scavenger NAD299 5HT1A Anxiety/Depres II >2002 >2002 antagonist sion AR-A2 5HT1E Anxiety/Depres PC >2002 >2002 antagonist sion remacemide NMDA Epilepsy III >2002 >2002 antagonist Parkinson's II >2002 >2002 Disease III 3Q 2001 3Q 2001 Huntington's chorea Infection AZD2563 Oxazolidinone Gram positive PC 4Q 4Q antibiotic infections, 2003 2003 including multi- resistant strains ME609 (Medivir Antiviral Topical herpes III 2001 2001 joint develop- ment) AstraZeneca R&D Pipeline: Line Extensions Cardiovascular Compound Mechanism Indication Phase Estimated Filing MMA NDA Seloken ZOC/ Toprol XL Atacand Zestril Gastrointestinal Losec Entocort Oncology Arimidex Aromatase Adjuvant Breast III 4Q 2001 4Q inhibitor Cancer 2001 Casodex Anti-androgen Early Prostate III 4Q 2002 4Q Cancer 2002 Tomudex Thymidylate Other tumours II 4Q 2001 ----- synthase & inhibitor III Zoladex LHRH agonist Premenopausal III 3Q 2000 3Q Adjuvant Breast 2000 Cancer Respiratory Accolate Pulmicort Rhinocort Oxis All inhaled products - HFA (non CFC) metered dose inhalers Pain Control Naropin CNS Seroquel D2/5HT2 Granules 1Q 1Q antagonist 2001 2001 Seroquel D2/5HT2 Sustained 4Q 4Q antagonist release 2001 2001 Seroquel D2/5HT2 Mania 4Q 4Q antagonist 2002 2001 Zomig RapimeltTM Launched 2Q 2000 Zomig Addescents 2Q 4Q 2001 2001 Zomig Nasal spray 2Q 2Q 2000 2000 Infection Merrem Carbapenem Hospital & III 3Q antibiotic community 2000 acquired pneumonia Merrem Carbapenem Use in III 3Q antibiotic Neutrapenics 2001 Merrem Carbapenem Cystic III 3Q antibiotic Fibrosis 2001 Foscavir Antiviral CMV in bone III 2001 2001 marrow depression AstraZeneca R&D Pipeline: Discontinued Compounds Cardiovascular Compound Mechanism ZD6169 K+ channel opener ZD7851/9720 OSC inhibitors ZD1611/4054 Endothelin A antagonists Gastrointestinal ropivacaine gel Inflammatory bowel disease PTH Osteoporosis Oncology ZD2767/9063 Antibody directed enzyme pro-drugs ZD4190 VTK ZD9481 Tyrosine kinase inhibitor ZD0101 Anti-angiogenic ZD3980 Anti-androgen Respiratory RPL(rofleponide) Asthma TH2 Project Asthma Mast Cell inhibitor Asthma ZD1611/4054 Endothelin A antagonists Pain Control Chirocaine Local anaesthetic Cell Therapy (ACTID) Chronic pain ZD4953/6804 EP1 antagonists CNS ATM027 Multiple sclerosis ZD9379 Glycine antagonist

Companies

AstraZeneca (AZN)
UK 100
FTSE quotes by TradingView

Latest directors dealings

All directors dealings today